Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. - Wikidata - awgldk - TriplyDB

Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging.

Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging.

http://www.wikidata.org/entity/Q35198160

about

Validation of functional imaging as a biomarker for radiation treatment response The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities Positron emission tomography to assess hypoxia and perfusion in lung cancer Molecular mechanisms of hypoxia in cancer.Hypoxia in head and neck cancer in theory and practice: a PET-based imaging approach Hypoxia as a biomarker for radioresistant cancer stem cells.F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy Predicting outcomes in radiation oncology--multifactorial decision support systems Correlation of FMISO simulations with pimonidazole-stained tumor xenografts: A question of O2 consumption?Tumour microenvironment heterogeneity affects the perceived spatial concordance between the intratumoural patterns of cell proliferation and 18F-fluorothymidine uptake A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients Repeatability of hypoxia PET imaging using [¹⁸F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity.Kill-painting of hypoxic tumours in charged particle therapy.[(68) Ga]-HP-DO3A-nitroimidazole: a promising agent for PET detection of tumor hypoxia Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer Functional MRI for radiotherapy dose painting.Pharmacokinetic modeling of a novel hypoxia PET tracer [18F]HX4 in patients with non-small cell lung cancer.In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions.Positron emission tomography radiotracers for imaging hypoxia.Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.Radiopharmaceuticals as probes to characterize tumour tissue.Molecular imaging of hypoxia in non-small-cell lung cancer.Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy - the influence of the choice of the reference region and conversion function.Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.FMISO as a Biomarker for Clinical Radiation Oncology.Quantitative Analysis of [18F]FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with Immunohistochemistry.Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription.Thermal combination therapies for local drug delivery by magnetic resonance-guided high-intensity focused ultrasound.Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma.Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model.Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response.How to Modulate Tumor Hypoxia for Preclinical In Vivo Imaging Research

P2860

Q26823165-D3685999-9839-40B0-980B-6576342E66D4 Q27025579-2C0CAF70-671E-431C-83C9-2D85F2AB0367 Q27026940-0EAB47E3-5BCD-4DE1-86EA-F94EC4C1F633 Q33705108-4C80B7A3-5D17-4DA8-B404-7B8DA2FE2B5F Q34151551-B21D3B5D-4139-4863-ACC6-BDFC48133074 Q34420732-B323AB57-723E-4969-9BFA-DE2A62A9A2A0 Q35116993-D9215E21-90F4-4B5D-9F8B-290E4F3AB22D Q36014711-8D4CD36B-C916-4D83-A2A3-821F36D37E99 Q36066409-DD1842AA-DE80-4B54-B785-B6924E0671AD Q36070106-E53D5B91-F26E-4733-9AE4-267253251339 Q36106434-B0716501-852F-4257-8E60-9064A93B4955 Q36109283-8A93E697-79E3-4268-B396-1472A0E0AE57 Q36177290-51E41EEB-BD96-4A8E-AB61-0F3B7324C472 Q36310285-3E723908-5CD4-4778-A401-16D89658BCD1 Q36414969-B143D2F8-6BA9-45F7-B7C5-3B87DC578F76 Q37306472-686CF47A-381A-44A3-8131-6FA47F781747 Q37467524-B0AFAF15-904A-47FC-AA0A-83C03AA70A8D Q37496776-7B62B6A5-2259-4647-B833-708D4E167BE3 Q37581964-50B2EF3F-9283-449E-A59D-7D49D6B0FECA Q38040666-EDFD83DE-F230-405F-82D8-26F78017B9CC Q38166980-C2FA95C0-7F68-4B6C-9155-1A5B17EECF98 Q38263008-9A44206D-FCCC-417E-84D5-611AF8D755F3 Q38342458-6C1A36A0-FC36-48A4-B59B-EA95B4B2D804 Q38363234-48A38DA6-B8C3-4981-AA92-7EDD4A7F59FC Q38401218-09289C9B-6416-4A54-92AA-527C226A2A54 Q38608607-C71CADF0-B0CB-4B1B-8E06-C215DE560015 Q38869449-801C72A2-031C-43F4-ADAD-5D74A02C94A8 Q39630464-838C47D3-0CBA-42EA-9BB0-BE10336BC0E5 Q39668588-B3329323-3E8C-4C58-9011-4A5798F42369 Q47591784-1A60204D-4274-498B-B382-CD3340093352 Q50239354-0161AF1B-6A4A-4973-AF21-6D551F47C3D8 Q50575883-F6524C94-E108-4965-9561-1DDC7D49D340 Q51559766-21095952-A075-4E17-B8EA-DD8C54EEEB12 Q52629217-553DBB38-B651-4A45-ABF5-9AC933111358 Q58695229-30ADD701-B46A-4B14-8B2E-0B85819690C7

P2860

Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging.

http://www.wikidata.org/entity/Q35198160

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Preclinical evaluation and val ...... ypoxia marker for PET imaging.

@ast

Preclinical evaluation and val ...... ypoxia marker for PET imaging.

@en

type

label

Preclinical evaluation and val ...... ypoxia marker for PET imaging.

@ast

Preclinical evaluation and val ...... ypoxia marker for PET imaging.

@en

prefLabel

Preclinical evaluation and val ...... ypoxia marker for PET imaging.

@ast

Preclinical evaluation and val ...... ypoxia marker for PET imaging.

@en

P1433

Q35198160-CD7F93DD-D8E5-4ED2-A0C3-8C237CAE026C

P1476

Q35198160-77873137-35B4-41EE-BEEB-9FAD6F7405FD

P2093

Q35198160-0D5400C9-1C76-47D1-996B-1D63E36879E8

Q35198160-2039C939-FBE0-4C6D-B9B6-7CBBD95C908A

Q35198160-8B86AEAC-5517-49F0-812A-367EDCEDA4FA

Q35198160-9C8DECA4-31E8-40BA-8524-9251F7E97176

Q35198160-BF29372A-7E8E-41DA-8797-0266CABBF6B5

Q35198160-CA9CDCA0-5256-4B99-BCCC-299EEBFBF937

Q35198160-E9712372-42FD-4DE0-81B1-EC8C61170529

Q35198160-EC03BE81-EBCE-4852-A569-0FE104E0F330

Q35198160-EF483EDC-293C-42DB-95AF-C3FDF2A2C951

Q35198160-F27E4D32-9EB2-4EF7-BCB5-997B7232DC17

P2860

Q35198160-08F4A93F-FA72-4ADC-B8C6-9C88DAFEB6DF

Q35198160-252A0A20-C5CE-4FAB-B231-EA6612B85815

Q35198160-2D41753D-602D-4569-BDB9-94CDBE22398C

Q35198160-2DFEE72C-C0C8-4D5A-82FB-87C46F16D5A1

Q35198160-353337BA-0D90-4ED5-839B-77F1B83663C9

Q35198160-37747C90-49BE-47E3-9E61-196B8CD2E078

Q35198160-39ABA77E-12A0-4536-BEA5-787256C3BFD5

Q35198160-40F848DB-310C-45B9-85D0-AE1D70490792

Q35198160-56E10036-C7F8-4598-8AF5-55D9D596D8E2

Q35198160-5C0F8F63-CAF4-4614-A04F-CB5D0EE68B4F

P304

Q35198160-E2F50788-BB2D-406D-942A-93FEE2C8D8D8

P31

Q35198160-B65FE82C-84CD-41DF-8BE7-7A9B63972E7A

P356

Q35198160-7730C869-64EB-4739-B45B-DE74FE2804CC

P407

Q35198160-CF724ACB-222E-4E28-B5B9-5772E8293894

P433

Q35198160-5CF0BD26-0123-47DE-BADE-B229C6510F6C

P478

Q35198160-6CF0EB10-7435-49AE-8E43-E24ACBB990D8

P50

Q35198160-7AA2A5AA-687E-47C0-A3C6-481E13BB82A5

Q35198160-C91C9780-BC11-4CE8-8BB0-1ABAD1F85A9F

P577

Q35198160-9272BD39-7133-4C8B-85FF-715333466DF8

P5875

Q35198160-9FBA4BF8-655A-4924-8DEB-9556DB78C56A

P698

Q35198160-B132B886-DB18-45BE-8882-67A1127BE00C

P921

Q35198160-5E415687-AA5D-4C07-AA15-31261AE63BB6

P932

Q35198160-E9BB71FE-B03D-4780-9AD5-A03558B59A0C

P356

PNAS.1102526108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Preclinical evaluation and val ...... ypoxia marker for PET imaging.

@en

P2093

Albert van der Kogel

http://www.w3.org/2001/XMLSchema#string

Guus A M S van Dongen

http://www.w3.org/2001/XMLSchema#string

Hartmuth C Kolb

http://www.w3.org/2001/XMLSchema#string

Joseph C Walsh

http://www.w3.org/2001/XMLSchema#string

Ludwig J Dubois

http://www.w3.org/2001/XMLSchema#string

Marco H M Janssen

http://www.w3.org/2001/XMLSchema#string

Michel C Ollers

http://www.w3.org/2001/XMLSchema#string

Natasja G Lieuwes

http://www.w3.org/2001/XMLSchema#string

Philippe Lambin

http://www.w3.org/2001/XMLSchema#string

Wenny J M Peeters

http://www.w3.org/2001/XMLSchema#string

P2860

Exploiting tumour hypoxia in cancer treatment

Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas.

[18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study

Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).

Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor.

Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT

Tumor hypoxia imaging.

Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.

Effect of carbogen breathing on tumour microregional blood flow in humans.

Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole.

P304

14620-14625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1102526108

http://www.w3.org/2001/XMLSchema#string

P407

P433

35

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Albert D. Windhorst

P577

2011-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51601281

http://www.w3.org/2001/XMLSchema#string

P698

21873245

http://www.w3.org/2001/XMLSchema#string

P921

P932

3167561

http://www.w3.org/2001/XMLSchema#string